Search
Selumetinib
go.drugbank.com/drugs/DB11689ApprovedInvestigational[A193608] It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system … Most recently, on November 20, 2025, the FDA expanded this indication to include adults [L53881]
Halazepam
go.drugbank.com/drugs/DB00801ApprovedIllicitWithdrawn[A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. … [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]
Rituximab
go.drugbank.com/drugs/DB00073ApprovedInvestigationalOn November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808]. … It was originally approved by the U.S.
Products: MABTHERA ® CONCENTRADO DE SOLUCIÓN PARA INFUSIÓN 500 MG / 50 MLDelandistrogene moxeparvovec
go.drugbank.com/drugs/DB16802ApprovedInvestigational[A260256] DMD tends to be more prevalent in males. … It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).
Clobetasol propionate
go.drugbank.com/drugs/DB01013ApprovedInvestigational[L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974.
Synonyms: Clobetasol propionate EInternational brands: Embeline ECinnarizine
go.drugbank.com/drugs/DB00568ApprovedInvestigationalCinnarizine is a specific calcium channel blocker that primarily works on the central vestibular system to interfere with the signal transmission between vestibular apparatus of the inner ear and the vomiting … centre of the hypothalamus.
Indalpine
go.drugbank.com/drugs/DB08953ApprovedWithdrawnIndalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. … However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeGlipizide
go.drugbank.com/drugs/DB01067ApprovedInvestigational[A179488] Compared to other members of the sulfonylurea drug group, glipizide displays rapid absorption and onset of action with the shortest half-life and duration of action, reducing the risk for long-lasting … [A179485] Glipizide was first approved by the FDA in 1994 and is available in extended-release tablets under the brand name Glucotrol®, as well as in combination with metformin under the brand name Metaglip
Products: GLUCOTROL XL TABLETAS DE 20MGSarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalBased upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental … The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well [L4814].
Tolevamer
go.drugbank.com/drugs/DB01344ApprovedIt may be taken orally or by rectum, as an enema, and functions as a potassium-binding resin in the intestines. … Sodium polystyrene sulfonate is a medication used to treat abnormally high potassium levels.